Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Status:
Completed
Trial end date:
2008-11-11
Target enrollment:
Participant gender:
Summary
RATIONALE: Collecting samples of tumor tissue and blood from patients with cancer to study in
the laboratory may help doctors learn how patients respond to treatment.
PURPOSE: This clinical trial is looking at tumor tissue samples from patients receiving
imatinib mesylate for malignant glioma to see how much imatinib mesylate is found in the
tumor tissue.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins